The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
The transaction marks a clear portfolio reshuffle for Indoco
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions
Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
Subscribe To Our Newsletter & Stay Updated
